Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **O-polysaccharide moiety of Pseudomonas aeruginosa serotype O11** is the variable, immunodominant carbohydrate chain extending from the outer membrane lipopolysaccharide (LPS) of this Gram-negative opportunistic pathogen[1][2][3][5]. It consists of repeating oligosaccharide units unique to serotype O11, structurally characterized by [-3)-α-L-FucNAc-(1-3)-β-D-FucNAc-(1-2)-β-D-Glc-(1-] (where FucNAc is N-acetylfucosamine)[1]. This structure defines the serogroup and is a key target of host immune response, serving as a major determinant of serotype-specific virulence, immune recognition, and epidemiology. It is also the immunological basis for certain vaccine strategies, as its surface exposure and specificity make it a prime target for antibody-mediated protection. There are no direct small-molecule therapeutics targeting this moiety, but recombinant or vaccine candidates have been engineered to stimulate immunity against strains harboring this antigen[1].
Induction of a protective immune response (targeted by vaccines to stimulate host immunity)[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on O-polysaccharide moiety of Pseudomonas aeruginosa serotype O11.